arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

DiaMedica Therapeutics Inc.

DMAC
$6.77 ▲ +0.10 (+1.50%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
35 Visible periods
23 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

DiaMedica Therapeutics Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $364.2M
Dividend Yield
Revenue Growth
Op. Margin None
ROIC -22.2%
FCF / Share $-0.17
Trailing P/E
Price / Book 7.7x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 6, 2026.

35-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-10.04M
↓ -30.3%
FCF / Share Free cash flow per share
$-0.17
↓ -1.1%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
15
Cash Quality
60

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 35 quarters